期刊
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
卷 130, 期 -, 页码 151-159出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2019.04.003
关键词
Histone deacetylase; HDAC inhibitors; Cardiac hypertrophy; Fibrosis; Metabolism; Heart failure; Diabetic cardiomyopathy
资金
- Canadian Institutes of Health Research [FRN-216927]
- The Shine On Foundation
- Baker Heart and Diabetes Institute
Histone deacetylases (HDACs) regulate gene transcription by catalyzing the removal of acetyl groups from key lysine residues in nucleosomal histones and via the recruitment of other epigenetic regulators to DNA promoter/enhancer regions. Over the past two decades, HDACs have been implicated in multiple processes pertinent to cardiovascular and metabolic diseases, including cardiac hypertrophy and remodeling, fibrosis, calcium handling, inflammation and energy metabolism. The development of small molecule HDAC inhibitors and genetically modified loss- and gain-of-function mouse models has allowed interrogation of the roles of specific HDAC isoforms in these processes. Isoform-selective HDAC inhibitors may prove to be powerful therapeutic agents for the treatment of cardiovascular diseases, obesity and diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据